Table 2.

Risk of first atherosclerotic and congestive heart failure events in the overall population by baseline levels of FGF-23

VariableFGF-23
<96.0 RU/ml96.0–145.4 RU/ml145.5–238.9 RU/ml≥239.0 RU/mlContinuous per Doublinga
Atherosclerotic events
 Events (n)476278100
 Incidence per 1000 person-years12.517.824.035.1
 HR (95% CI)
  UnadjustedbReference1.41 (1.08 to 1.85)1.90 (1.36 to 2.66)2.75 (2.19 to 3.46)1.37 (1.25 to 1.50)
  Adjusted for demographic variables/kidney function cReference1.27 (0.97 to 1.66)1.54 (1.12 to 2.13)2.13 (1.68 to 2.69)1.30 (1.16 to 1.46)
  Adjusted for traditional risk factors dReference1.32 (0.90 to 1.92)1.47 (1.14 to 1.90)1.76 (1.20 to 2.59)1.24 (1.09 to 1.40)
  Adjusted for nontraditional risk factorseReference1.34 (0.90 to 1.98)1.46 (1.11 to 1.91)1.63 (1.03 to 2.59)1.23 (1.04 to 1.45)
Congestive heart failure hospitalization
 Events (n)305296182
 Incidence per 1000 person-years7.914.729.565.9
 HR (95% CI)
  UnadjustedbReference1.85 (1.12 to 3.05)3.69 (2.11 to 6.46)8.18 (5.47 to 12.24)1.75 (1.64 to 1.88)
  Adjusted for demographic variables/kidney functioncReference1.45 (0.88 to 2.39)2.23 (1.23 to 4.03)4.40 (2.96 to 6.53)1.58 (1.51 to 1.65)
  Adjusted for traditional risk factorsdReference1.36 (0.78 to 2.38)1.74 (1.06 to 2.86)2.98 (1.97 to 4.52)1.45 (1.28 to 1.65)
  Adjusted for nontraditional risk factorseReference1.29 (0.69 to 2.40)1.57 (0.86 to 2.87)2.64 (1.59 to 4.39)1.39 (1.22 to 1.58)
  • a Risk per 1-unit change in log2(FGF-23).

  • b All models are clustered by clinical center.

  • c Adjusted for age, sex, race/ethnicity, income, eGFR, and urine albumin-to-creatinine ratio.

  • d Adjusted for covariates in the demographic and kidney function adjusted model, plus history of hypertension; hypercholesterolemia; history of atherosclerotic cardiovascular disease; history of congestive heart failure; diabetes; control of BP to <140/90 mmHg; hemoglobin A1c; smoking status; body mass index; waist circumference; serum triglycerides; LDL cholesterol; use of antiplatelet medications, angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, β-blockers, statins, and loop diuretics; and the number of prescribed classes of BP medications.

  • e Adjusted for covariates in the traditional risk factor– and medication-adjusted model, plus serum phosphate, calcium, albumin, C-reactive protein, PTH, and hemoglobin.